The key opinion leader discusses how criteria for assisted reproductive technology (ART) coverage are established, including stepwise approaches and considerations for mixed protocols, while emphasizing the importance of collaboration between providers and payers to ensure patient access to various ARTs.
Video content above is prompted by the following:
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More